This PDF is the current document as it appeared on Public Inspection on 10/02/2012 at 08:45 am.
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the withdrawal approval of a new animal drug application (NADA) and three abbreviated new animal drug applications (ANADAs) at the sponsors' request because the products are no longer manufactured or marketed.
This rule is effective October 15, 2012.
FOR FURTHER INFORMATION CONTACT:
David Alterman, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-453-6843, email: email@example.com.
The sponsors of the NADA and ANADAs listed in table 1 have requested that FDA withdraw approval because the products are no longer manufactured or marketed:
|NADA/ANADA No.||Trade name (drug)||Applicant||Citation in 21 CFR|
|100-556||Vigorena Feeds Hy-Ty Premix (tylosin phosphate)||Springfield Milling Corp., Vigorena Feeds, Springfield, MN 56087||558.625|
|200-435||RESPIRAM (doxapram hydrochloride) Injection||Modern Veterinary Therapeutics, LLC, 18001 Old Cutler Rd., suite 317, Miami, FL 33157||522.775|
|200-446||BUTORPHINE (butorphanol tartrate) Injection||Modern Veterinary Therapeutics, LLC, 18001 Old Cutler Rd., suite 317, Miami, FL 33157||522.246|
|200-459||VETAZINE (triamcinolone) Cream||Modern Veterinary Therapeutics, LLC, 18001 Old Cutler Rd., suite 317, Miami, FL 33157||524.2483|
Elsewhere in this issue of the Federal Register, FDA gave notice that approval of NADA 100-556 and ANADAs 200-435, 200-446, and 200-459, and all supplements and amendments thereto, is withdrawn, effective October 15, 2012. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these voluntary withdrawals of approval.
Following these withdrawals of approval, Modern Veterinary Therapeutics, LLC, and Springfield Milling Corp. will no longer be the sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for these firms.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
List of Subjects
- Administrative practice and procedure
- Animal drugs
- Reporting and recordkeeping requirements
Therefore, under the Federal Food, Drug, and Cosmetic Act and under the authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 522, 524, and 558 are amended as follows:
PART 510—NEW ANIMAL DRUGS
1. The authority citation for
2. In § 510.600, in the table in paragraph (c)(1), remove the entries for “Modern Veterinary Therapeutics, LLC” and “Springfield Milling Corp.”; and in the table in paragraph (c)(2), remove the entries for “015914” and “035955”.
PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
3. The authority citation for
4. In § 522.246, in paragraph (b)(2), remove “Nos. 015914 and 059130” and in its place add “No. 059130”.
5. In § 522.775, in paragraph (b), remove “Nos. 000010 and 015914” and in its place add “No. 000010”.
PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
6. The authority citation for
7. In § 524.2483, in paragraph (b), remove “015914,”.
PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
8. The authority citation for
9. In § 558.625, remove and reserve paragraph (b)(40).
Dated: September 27, 2012.
Director, Center for Veterinary Medicine.
[FR Doc. 2012-24331 Filed 10-2-12; 8:45 am]
BILLING CODE P